Journal article

Sensitivity to Chronic Methamphetamine Administration and Withdrawal in Mice with Relaxin-3/RXFP3 Deficiency

Mouna Haidar, Monica Lam, Berenice E Chua, Craig M Smith, Andrew L Gundlach

NEUROCHEMICAL RESEARCH | SPRINGER/PLENUM PUBLISHERS | Published : 2016

Abstract

Methamphetamine (METH) is a highly addictive psychostimulant, and cessation of use is associated with reduced monoamine signalling, and increased anxiety/depressive states. Neurons expressing the neuropeptide, relaxin-3 (RLN3), and its cognate receptor, RXFP3, constitute a putative 'ascending arousal system', which shares neuroanatomical and functional similarities with serotonin (5-HT)/dorsal raphe and noradrenaline (NA)/locus coeruleus monoamine systems. In light of possible synergistic roles of RLN3 and 5-HT/NA, endogenous RLN3/RXFP3 signalling may compensate for the temporary reduction in monoamine signalling associated with chronic METH withdrawal, which could alter the profile of 'beha..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia


Funding Acknowledgements

This research was supported by National Health and Medical Research Council of Australia Project Grants 1005988 and 1024885 (ALG), grants from the Pratt and Besen Family Foundation (ALG), a Brain & Behavior Research Foundation (USA) NARSAD Independent Investigator Award (ALG), and the Victorian Government Operational Infrastructure Support Programme. MH is the recipient of a postgraduate scholarship from the Alzheimer's Australia Dementia Research Foundation. The authors thank Timothy Lovenberg and Steve Sutton (Janssen Companies of Johnson & Johnson, San Diego, CA, USA) for commissioning and providing the original Rln3 and Rxfp3 knockout mice.